Kyverna Therapeutics, Inc.
KYTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $132,702 | $83,406 | $161,624 |
| - Cash | $34,164 | $53,440 | $56,865 | $96,621 |
| + Debt | $1,339 | $5,918 | $6,938 | $8,242 |
| Enterprise Value | – | $85,180 | $33,479 | $73,245 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$415 | -$515 | -$501 | -$563 |
| % Margin | – | – | – | – |
| EBITDA | -$36,365 | -$41,552 | -$44,109 | -$36,899 |
| % Margin | – | – | – | – |
| Net Income | -$36,787 | -$42,081 | -$44,635 | -$37,489 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.85 | -0.97 | -1.03 | -0.87 |
| % Growth | 12.4% | 5.8% | -18.4% | – |
| Operating Cash Flow | -$43,321 | -$31,949 | -$44,915 | -$37,061 |
| Capital Expenditures | -$392 | -$204 | $0 | -$532 |
| Free Cash Flow | -$43,713 | -$32,153 | -$44,915 | -$37,593 |